UK Companies House feature
TANABE PHARMA EUROPE LTD
Profile
- Company number
- 04134678
- Status
- Active
- Incorporation
- 2001-01-03
- Last accounts made up
- 2025-03-31
- Account category
- FULL
- Primary SIC
- 64991
- Hubs
- UK Fintech
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Financial forecasts for profits and cash flows indicate that the company does not expect any significant downturn. The company has no borrowings. However, the company has significant cash balances and has considerably good financial resources with strong net and current assets at year-end and at date of sign off and the stress testing indicate no issues. As a consequence, the directors believe that the company is well-placed to manage its business risks successfully despite the current economic conditions. Accordingly, the directors consider that the company will be able to settle its liabilities as these fall due for a period of twelve months from the date that these accounts are signed and the accounts have been prepared on a going concern basis.”
Subsidiaries
- Mitsubishi Tanabe Pharma GmbH · 100% held · Germany · Sales and marketing
Significant events
- “The office lease was terminated on 7th March 2025 at the break option. The commencement of new office lease is 6th May 2025 therefore the relating asset and the liability will be recognised on the commencement date. The new lease agreement was signed on 8th May 2025.”
- “Mitsubishi Chemical Group (MCG) has decided to transfer all shares of our parent company, Mitsubishi Tanabe Pharma Corporation (MTPC), along with all its wholly owned subsidiaries (including MTPE), to Bain Capital. This transfer is scheduled to take place in 2025.”
- “We discontinued the Herbesser business in FY2023 and divested the Argatroban business in FY2024.”
- “Following the divestment of Argatroban, a transitional service agreement was established to support the buyer during the transition period.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 40 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| KIM, Jungkeun | Secretary | 2023-01-31 | — | — |
| DAVIES, Martin Wyn, Dr | Director | 2006-01-01 | Jul 1957 | British |
| TADA, Toshifumi | Director | 2024-04-01 | Jul 1970 | Japanese |
Show 40 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CHIBA, Masatoshi | Secretary | 2020-01-10 | 2023-01-31 |
| CRAWFORD, William Duncan | Secretary | 2001-09-25 | 2016-07-29 |
| DURWARD, Tina Ann | Secretary | 2016-08-09 | 2017-08-31 |
| MAEDA, Kazutaka | Secretary | 2017-08-31 | 2020-01-10 |
| MIKUNI, Toshiaki | Secretary | 2001-03-08 | 2001-09-25 |
| CLIFFORD CHANCE SECRETARIES LIMITED | Corporate Nominee Secretary | 2001-01-03 | 2001-03-08 |
| AZUMA, Hiroshi | Director | 2022-04-12 | 2024-04-01 |
| AZUMA, Hiroshi | Director | 2016-10-01 | 2020-04-01 |
| CHIBA, Masatoshi | Director | 2019-04-01 | 2023-01-31 |
| FUJIMORI, Shinichiro | Director | 2002-03-01 | 2003-06-30 |
| HASHIMOTO, Atsushi | Director | 2024-09-01 | 2025-11-01 |
| IKOMA, Hidenobu, Dr | Director | 2006-07-01 | 2007-10-01 |
| ISHIDA, Hayato | Director | 2010-08-01 | 2011-04-01 |
| KAMBAYASHI, Noriaki | Director | 2012-10-01 | 2016-09-30 |
| KATSUYAMA, Takashi | Director | 2001-10-01 | 2002-04-01 |
| KAWAKAMI, Yasutoshi | Director | 2020-04-01 | 2024-04-01 |
| KAWASHIMA, Kazutaka | Director | 2012-03-29 | 2015-10-01 |
| KISHI, Takayasu | Director | 2004-06-29 | 2005-06-29 |
| KUKI, Hideki | Director | 2020-04-01 | 2022-04-12 |
| KUKI, Hideki | Director | 2015-10-01 | 2016-09-30 |
| LAYTON, Matthew Robert | Nominee Director | 2001-01-03 | 2001-03-08 |
| MATSUURA, Takashi | Director | 2006-01-01 | 2009-03-31 |
| MIKUNI, Toshiaki | Director | 2009-04-01 | 2014-02-01 |
| MOGI, Takashi | Director | 2011-04-01 | 2012-03-29 |
| MURAKAMI, Seiichi | Director | 2009-06-19 | 2010-08-01 |
| MURAKAMI, Shu | Director | 2003-07-01 | 2004-06-29 |
| NAMBA, Junya | Director | 2018-04-01 | 2020-04-01 |
| NARIMATSU, Akihiro, Dr | Director | 2004-12-03 | 2006-07-01 |
| ONO, Akihisa | Director | 2001-03-08 | 2002-03-22 |
| RICHARDS, Martin Edgar | Nominee Director | 2001-01-03 | 2001-03-08 |
| SHIMOSAKON, Akira | Director | 2005-07-01 | 2010-08-01 |
| SHIMOSAKON, Akira | Director | 2001-10-01 | 2003-06-30 |
| SUZUKI, Fumio | Director | 2016-10-01 | 2018-04-01 |
| TAKAGI, Takehiro | Director | 2003-07-01 | 2006-01-01 |
| TAKAHASHI, Masami | Director | 2010-08-01 | 2011-02-01 |
| TANABE, Ryosuke, Managing Director | Director | 2016-10-01 | 2018-04-01 |
| TANAKA, Eiji | Director | 2011-02-01 | 2012-10-01 |
| TOBE, Akihiro | Director | 2001-10-01 | 2007-06-21 |
| YANAGISAWA, Kenichi | Director | 2007-10-01 | 2009-06-19 |
| YATO, Michihisa | Director | 2018-04-01 | 2019-04-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Tanabe Pharma Corporation | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 196 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-03-02 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2026-02-27 | CH01 | officers | change person director company with change date |
| 2026-01-15 | CH01 | officers | change person director company with change date |
| 2026-01-12 | CH01 | officers | change person director company with change date |
| 2026-01-07 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2026-01-06 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2025-12-04 | MA | incorporation | memorandum articles |
| 2025-12-04 | RESOLUTIONS | resolution | resolution |
| 2025-12-03 | CC04 | change-of-constitution | statement of companys objects |
| 2025-12-01 | CERTNM | change-of-name | certificate change of name company |
| 2025-11-05 | TM01 | officers | termination director company with name termination date |
| 2025-06-23 | AA | accounts | accounts with accounts type full |
| 2025-01-06 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-11-05 | CH01 | officers | change person director company with change date |
| 2024-09-13 | AP01 | officers | appoint person director company with name date |
| 2024-08-12 | AA | accounts | accounts with accounts type full |
| 2024-04-01 | AP01 | officers | appoint person director company with name date |
| 2024-04-01 | TM01 | officers | termination director company with name termination date |
| 2024-04-01 | TM01 | officers | termination director company with name termination date |
| 2024-01-03 | CS01 | confirmation-statement | confirmation statement with no updates |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.